


# Expanding the arsenal of drugs for use against COVID-19


December 9 2022



**3 (X = O)**  
 $IC_{50}$ :  $0.037 \pm 0.0010 \mu M$   
 $EC_{50}$ :  $0.29 \pm 0.056 \mu M$

↓ **Satisfactory  
PK profiles**

**4 (X = S)**  
 $IC_{50}$ :  $0.37 \pm 0.015 \mu M$   
 $EC_{50}$ :  $0.34 \pm 0.015 \mu M$



Graphical Abstract. Credit: *iScience* (2022). DOI: 10.1016/j.isci.2022.105365

The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world. While the vaccination program is advancing, drug treatments for COVID-19 are still highly important for those who become infected.

Now, a team at Tokyo Medical and Dental University (TMDU), National Center for Global Health and Medicine (NCGM), Tohoku University, NCI/NIH, and Kumamoto University has designed and synthesized compounds that have the potential to be [novel drugs](#) targeting SARS-CoV-2.

The SARS-CoV-2 virus contains an enzyme called the "main protease", or  $M^{\text{pro}}$ , that cleaves other proteins encoded in the SARS-CoV-2 genome as part of viral activity and replication.  $M^{\text{pro}}$  is an important and appealing target for drugs treating COVID-19 because it is both essential for [viral replication](#) and very different from any human molecules, so drugs targeting  $M^{\text{pro}}$  are likely to have few side effects and be very effective.

When testing a panel of compounds known to have inhibitory activity against SARS-CoV, the virus responsible for the 2002 SARS outbreak, the team identified a compound named 5h/YH-53 that showed some activity inhibiting SARS-CoV-2  $M^{\text{pro}}$ , but was inefficient and unstable. Therefore, they used 5h as a starting point to develop other compounds with increased efficiency and stability.

"Our strategy involved introducing [fluorine atoms](#) into the part of the molecule responsible for inhibiting  $M^{\text{pro}}$  to increase its binding affinity, as well as replacing a bond within 5h that is easily broken down by the

liver with a different structure to increase biostability," explains lead author Kohei Tsuji.

"Of the compounds we developed, compound 3 showed high potency and was able to block SARS-CoV-2 infection in vitro without any viral breakthrough," explains senior author Hirokazu Tamamura. "Compound 4, a derivative of compound 3 in which an easily broken-down amide bond had been replaced with a stable thioamide bond, also showed remarkable anti-SARS-CoV-2 activity."

Although compound 4 had lower  $M^{pro}$  inhibitory activity than compound 3, the increased stability meant that the overall activity of compound 4 was comparable to that of compound 3.

When they tested these [novel compounds](#) on a variety of strains of SARS-CoV-2, compound 3 was as effective on mutant strains of the virus as on the ancestral Wuhan strain. Additionally, neither compound 3 or 4 showed any toxicity to cultured cells. These data suggest that these compounds show high potential as [drug treatments](#) for COVID-19.

An expanded range of drug choices is important for treating disease, so the development of efficient drugs to target the novel SARS-CoV-2 virus is highly important. This work identifies two compounds as potential drugs, and further development of these compounds continues. It also proves the principle that easily broken-down amide bonds can be replaced with thioamide bonds in drug development to increase the stability of the resulting compounds.

Taken together, this is an important advance in both the wider [drug development](#) field as well as for drugs to treat COVID-19.

The study is published in the journal *iScience*.

**More information:** Kohei Tsuji et al, Potent and biostable inhibitors of the main protease of SARS-CoV-2, *iScience* (2022). [DOI: 10.1016/j.isci.2022.105365](https://doi.org/10.1016/j.isci.2022.105365)

Provided by Tokyo Medical and Dental University

Citation: Expanding the arsenal of drugs for use against COVID-19 (2022, December 9)  
retrieved 19 April 2024 from <https://medicalxpress.com/news/2022-12-arsenal-drugs-covid-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.